Jeffrey Nau is CEO of Oyster Point Pharma, a clinical stage pharmaceutical company focused on developing commercial therapies dealing with parasympathetic pathways. In a climate where oncology and rare diseases get most of the attention, Nau talks about what it’s like working on diseases that don’t get the same press, like dry eye, which is the focus of their current Phase 2 clinical trial. How this impacts raising capital and other bumps in the road he has come across. Having extensive experience with raising startup money, Nau outlines some best practices when it comes to funding.
Jeffrey Nau is CEO of Oyster Point Pharma, a clinical stage pharmaceutical company focused on developing commercial therapies dealing with parasympathetic pathways. In a climate where oncology and rare diseases get most of the attention, Nau talks about what it’s like working on diseases that don’t get the same press, like dry eye, which is the focus of their current Phase 2 clinical trial. How this impacts raising capital and other bumps in the road he has come across. Having extensive experience with raising startup money, Nau outlines some best practices when it comes to funding.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
